X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Pharmaco-resistant Neonatal Seizures: Critical Mechanistic Insights from a Chemoconvulsant Model.

Shivani C Kharod | Brandon M Carter | Shilpa D Kadam
Developmental neurobiology | 2018

Neonatal seizures are harmful to the developing brain and are associated with mortality and long-term neurological comorbidities. Hypoxic-ischemic encephalopathy (HIE) seizures represent a significant proportion of such seizures. Phenobarbital (PB) remains the first line anti-seizure drug (ASD) treatment but fails ~50% of the time. Translational models of neonatal seizures are crucial to investigating mechanisms underlying PB-resistance. A model of PB-resistant ischemic seizures in postnatal day 7 (P7) CD-1 mice reported K-Cl cotransporter 2 (KCC2) degradation that has been shown to be due to activation of the TrkB pathway. We investigated PB-efficacy in a pentylenetetrazole (PTZ) model of neonatal seizures in the same strain and age using identical treatment protocols to gain insights into mechanisms underlying PB-resistance. A single dose of PTZ (80 mg/kg; IP) consistently induced repetitive seizures that did not progress to status epilepticus (SE). PB (25 mg/kg; IP, single dose) significantly suppressed the PTZ-induced seizures. This was associated with significant KCC2 upregulation and stable Na-K-Cl cotransporter 1 (NKCC1) expression at 24h. The TrkB pathway was not activated. PTZ seizure burdens were significantly higher than those reported for ischemic seizures, indicating seizure severity did not dictate the differences in PB-efficacy. Bumetanide (BTN) (0.1-0.2 mg/kg; IP) did not work as an anti-seizure agent, similar to the ischemic model. When investigating mechanisms underlying the emergence of PB-resistance in translational models, the method by which seizures are induced may dictate mechanisms underlying emergence of PB-resistance.

Pubmed ID: 30136373 RIS Download

Additional research tools detected in this publication

None found

Associated grants

  • Agency: NICHD NIH HHS, United States
    Id: R01 HD090884

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


Alpha-Tubulin Mouse Monoclonal Antibody (antibody)

RRID:AB_2637092

This monoclonal targets alpha-Tubulin

View all literature mentions

Phospho-PLCgamma1 (Tyr783) Antibody (antibody)

RRID:AB_330855

This polyclonal targets Phospho-PLCgamma1 (Tyr783)

View all literature mentions

KCC2 Antibody (antibody)

RRID:AB_2721238

This monoclonal targets KCC2

View all literature mentions

Alpha-Tubulin Mouse Monoclonal Antibody (antibody)

RRID:AB_2637092

This monoclonal targets alpha-Tubulin

View all literature mentions

KCC2 Antibody (antibody)

RRID:AB_2721238

This monoclonal targets KCC2

View all literature mentions

Phospho-PLCgamma1 (Tyr783) Antibody (antibody)

RRID:AB_330855

This polyclonal targets Phospho-PLCgamma1 (Tyr783)

View all literature mentions

Alpha-Tubulin Mouse Monoclonal Antibody (antibody)

RRID:AB_2637092

This monoclonal targets alpha-Tubulin

View all literature mentions

Phospho-PLCgamma1 (Tyr783) Antibody (antibody)

RRID:AB_330855

This polyclonal targets Phospho-PLCgamma1 (Tyr783)

View all literature mentions

KCC2 Antibody (antibody)

RRID:AB_2721238

This monoclonal targets KCC2

View all literature mentions